In another SEER-based analysis, HR+/HER2+ tumor was reported to have the best prognosis (HR+/HER2+ vs HR+/HER2−: HR=0.85, 95% CI = 0.77–0.94, p <0.05) (13). The gene discussed is ERBB2; the disease is neoplasm.